

Table SI. Neoadjuvant chemotherapy regimens.

Regimen	Drugs	Cycles	Subtype	No. of patients
AC-T	Doxorubicin + cyclophosphamide + docetaxel	8 (4 cycles AC + 4 cycles T)	All	96
EC-T	Epirubicin + cyclophosphamide + docetaxel	8 (4 cycles AC + 4 cycles T)	All	144
TE	Paclitaxel + epirubicin	6	All	11
EC-TH	Epirubicin + cyclophosphamide → docetaxel + trastuzumab	8 (4+4)	8 (4+4)	27
AC-THP	Doxorubicin/epirubicin + cyclophosphamide + docetaxel/paclitaxel + trastuzumab + THP	8 (4+4)	HER2 ⁺	3
TCHP	Docetaxel + carboplatin + trastuzumab + THP	6-8	HER2 ⁺	3
TCbHP	Taxane (docetaxel) + carboplatin + herceptin (trastuzumab) + THP	6-8	HER2 ⁺	7
TCH/TCbH	Docetaxel + carboplatin + trastuzumab	6-8	HER2 ⁺	32

THP, pertuzumab.

Table SII. Sensitivity analysis: Multivariate logistic regression with ‘forced entry’ of age and tumor size groups in predicting pCR in the test set (n=226).

Characteristics	B value	OR	95% CI	P-value
Change in tumor diameter, %				
<50	Reference			
≥50	1.7	5.473	2.666-11.229	<0.001 ^a
Change in CA153 levels				
Increase	Reference			
Decrease	1.064	2.898	1.387-5.053	0.029 ^a
Margin				
Circumscribed	Reference			
Not circumscribed	2.167	8.732	3.802-20.066	<0.001 ^a
Molecular subtype				0.038 ^a
Luminal A	Reference			
Luminal B	0.198	1.219	0.674-4.373	0.681
HER2	0.987	2.683	0.931-9.738	0.068
TNBC	1.359	3.892	1.165-12.481	0.027 ^a
Age, years				
≥46	Reference			
<46	-0.37	0.691	0.394-1.211	0.196
Tumor diameter, cm				
≥2.1	Reference			
<2.1	0.947	2.578	0.783-8.481	0.119

^aP<0.05. OR, odds ratio; TNBC, triple-negative breast cancer; CI, confidence interval; HER2, human epidermal growth factor receptor 2; CA153, carbohydrate antigen 153.

Table SIII. Subgroup and interaction analyses of ultrasound margin in predicting pathological complete response.

Molecular type	OR of circumscribed margin	95% CI	P-value
TNBC (luminal ⁻ /HER2 ⁻ ; n=50)	1.875	0.482-7.372	0.133
Non-TNBC (Luminal ⁺ /HER2 ⁺ ; n=176)	1.827	1.015-4.389	0.067
Interaction (subtype x margin)	-	-	0.667
Interaction (CA153 x tumor diameter reduction)			0.420

TNBC, triple-negative breast cancer; OR, odds ratio; CI, confidence interval; HER2, human epidermal growth factor receptor 2; CA153, carbohydrate antigen 153.